Showing results (1-10 of 383) with videos related to
Sort By:
Pageof 39
Clinical Endocrinology|July 22, 2014
Adverse skeletal effects of drugs - beyond GlucocorticoidsSusannah O'Sullivan, Andrew GreyThe Journal of Clinical Endocrinology and Metabolism|January 29, 2009
Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinibSusannah O'Sullivan, Anne Horne, Diana Wattie, et al.Therapeutics and Clinical Risk Management|March 25, 2008
Differences between the bisphosphonates for the prevention and treatment of osteoporosisAndrew Grey, Ian R ReidExpert Opinion on Investigational Drugs|April 19, 2005
Emerging and potential therapies for osteoporosisAndrew Grey, Ian R ReidJournal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 1, 2007
Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanismsSusannah O'Sullivan, Dorit Naot, Karen Callon, et al.Calcified Tissue International|October 28, 2010
Imatinib mesylate does not increase bone volume in vivoSusannah O'Sullivan, Dorit Naot, Karen E Callon, et al.The Journal of Clinical Endocrinology and Metabolism|August 6, 2014
Differences in overlapping meta-analyses of vitamin D supplements and fallsMark J Bolland, Andrew Grey, Ian R ReidThe Lancet. Diabetes & Endocrinology|April 16, 2014
Skeletal health in adults with HIV infectionMark J Bolland, Andrew Grey, Ian R ReidLancet (London, England)|October 15, 2013
Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysisIan R Reid, Mark J Bolland, Andrew GreyThe New Zealand Medical Journal|September 17, 2014
Translation of research into clinical practice: a case study of calcium supplement prescribing in New ZealandMark J Bolland, Andrew Grey, Ian R ReidPageof 39